Capstone Investment Advisors, LLC Zentalis Pharmaceuticals, Inc. Transaction History
Capstone Investment Advisors, LLC
- $30.4 Billion
- Q3 2024
A detailed history of Capstone Investment Advisors, LLC transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Capstone Investment Advisors, LLC holds 13,066 shares of ZNTL stock, worth $25,086. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,066Holding current value
$25,086% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ZNTL
# of Institutions
138Shares Held
67.7MCall Options Held
48.5KPut Options Held
89.6K-
Matrix Capital Management Company, LP Waltham, MA14MShares$26.8 Million2.45% of portfolio
-
Eventide Asset Management, LLC Boston, MA8.55MShares$16.4 Million0.55% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$9.25 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.61MShares$8.86 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA3.11MShares$5.97 Million2.71% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $109M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...